Cooley has expanded its life sciences corporate partnering and licensing practice with the addition of partners Sarah Hogan and Jenna Ventorino in the Boston office and partner Stephen Abreu in the San Francisco office. The three new attorneys enhance Cooley’s established position as a leading strategic advisor across the life sciences industry. Hogan and Ventorino join from WilmerHale, and Abreu joins from Sidley Austin.
“We are excited to welcome these exceptional lawyers to Cooley as we continue to expand our market-leading life sciences platform from coast to coast and around the globe,” said Sonya Erickson, partner and global chair of Cooley’s business department. “Their collective talent will further strengthen our team and accelerate the momentum we’ve built across the life sciences sector and in the dynamic Boston and San Francisco markets.”
“These talented lawyers not only expand our market-leading life sciences practice but also elevate how we partner with clients to bring their innovative discoveries to market and achieve their business goals,” said Ken Krisko, partner and head of Cooley’s life sciences corporate partnering and licensing practice group. “Their arrival further exemplifies Cooley’s commitment to be at the forefront of the life sciences industry.”
The three partners bring expanded depth and geographical reach to Cooley’s premier life sciences partnering platform. Together, they leverage decades of experience to advise clients across the full life sciences life cycle on transformational deals that bring innovation to market. With scientific backgrounds and in-house counsel experience, the group shares a pragmatic approach that their clients rely on to structure deals that optimize the value of scientific assets.
“Cooley’s global life sciences platform is truly best in class,” said Hogan. “The firm has been at the forefront of the industry since the earliest days of biotech, helping companies grow from bold ideas into market leaders. I’m thrilled to join a team that thrives on collaboration and creativity, and to offer my clients the benefit of Cooley’s forward-thinking approach at every stage of their journey, from lab to market.”
Cooley’s full-service global life sciences capabilities are unmatched. The firm represents nearly 2,500 public and private life sciences clients worldwide, including almost 50% of the Nasdaq Biotechnology Index, and has a dedicated team of more than 45 life sciences strategic partnering and licensing lawyers. Clients include biotech, medtech and specialty pharmaceutical companies at the forefront of innovation, including cell and gene therapies, artificial intelligence-led drug discovery and new vaccine technologies. Cooley is Law360’s Life Sciences Group of the Year and has received multiple LMG Life Sciences EMEA (Europe, the Middle East and Africa) Awards, including Venture Capital Firm of the Year.
Source: www.cooley.com
